Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...

Their findings hold promise for advancing the development of preclinical ... has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the ...

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

NGS-based AML MRD is being more widely adopted in drug development and ... even a few residual leukemic cells provides a more comprehensive picture of the current AML status of a sample. OGT’s new ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.

Auron Therapeutics Inc. has received FDA clearance of its IND application for its oral KAT2A/B degrader AUTX-703 in hematological malignancies. A phase I proof-of-concept trial in acute myeloid ...

China Emerging Key Player in Development Of Gamma Delta T Cell Cancer Therapy Says KUICK RESEARCHDelhi, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Global Gamma Delta T Cell Cancer Therapy Market Opportunity ...